. Afsoon Emami Naini; . Nooshin Keyvandarian; . Mojgan Mortazavi; . Shahram Taheri; . Sayed Mohsen Hosseini
Volume 4, Issue 3 , July 2015, , Pages 135-141
Abstract
Objective: Hypertension and hyperlipidemia are two major risk factors for cardiovascular disease in continuous ambulatory peritoneal dialysis (CAPD) patients. This study was designed ...
Read More
Objective: Hypertension and hyperlipidemia are two major risk factors for cardiovascular disease in continuous ambulatory peritoneal dialysis (CAPD) patients. This study was designed to investigate the effect of omega-3 fatty acids on blood pressure (BP) and serum lipids in CAPD patients.Methods: This study was a randomized double‑blind clinical trial in which 90 CAPD patients were randomly assigned to either the omega‑3 or the placebo group. Patients in omega‑3 group received 3 g/day omega‑3 for 8 weeks, whereas patients in the control group received placebo. At baseline and at the end of 8 weeks, the patients’ BP was controlled, and serum biochemistry was measured.Findings: Mean systolic BP decreased (–22.2 ± 14.2 mmHg) in the omega‑3 group at the end of the study while in the placebo group increased (+0.5 ± 30.2 mmHg) (P < 0.0001). Mean diastolic BP of the omega‑3 group decreased more (–11.95 ± 11.9 mmHg) comparing with the placebo group (–1.1 ± 17.3 mmHg) (P = 0.001). There were no significant differences between the two groups in mean changes in serum triglyceride, and total, high‑density lipoprotein, and low‑density lipoprotein cholesterol.Conclusion: The results of this study indicate that omega‑3 reduced BP significantly but had no effect on lipid profile in our CAPD patients.